High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer - a phase I/II study

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 2013-2017

  Cameron, D A ^a   Craig, J ^b   Gabra, H ^a   Lee, L ^a   MacKay, J ^a   Parker, A C ^b   Leonard, R C F ^a   Anderson, E ^c   Anderson, T ^c   Chetty, U ^c   Dixon, M ^c   Hawkins, A ^c   Jack, W ^c   Kunkler, I ^c   Leonard, R ^c   Matheson, L ^c   Miller, W ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NONE

Author keywords

Breast cancer; High dose chemotherapy; Metastatic; Peripheral blood progenitor cells; Poor prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THIOTEPA;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HEMATOPOIESIS; HERPES ZOSTER; HUMAN; HUMAN CELL; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT;

EID: 8044240912     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.669     Document Type: Article

References (25)

1. ANTMAN KH. (1992). Dose-intensive therapy in breast cancer. In High-Dose Cancer Therapy Pharmacology, Hematopoietins, Stem Cells, Armitage JO and Antman KH. (eds) pp. 701-718. Williams & Wilkins: Baltimore.
2. ANTMAN K, AYASH L, ELIAS A, WHEELER C, HUNT M, EDER JP, TEICHER BA, CRITCHLOW J, BIBBO J, SCHNIPPER LE AND FREI E. (1992). A Phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol., 10, 102-110.
3. BEZWODA WR, SEYMOUR L AND DANSEY RD. (1995). High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. Clin. Oncol., 13, 2483-2489.
4. CRAIG JIO, SMITH SM, PARKER AC AND ANTHONY RS. (1992). The response of peripheral blood stem cells to standard chemotherapy for lymphoma. Leuk. Lymph., 6, 363-368.
5. CRAIG JIO, ANTHONY RS, STEWART A, THOMSON EB, GILLON J AND PARKER AC. (1993). Peripheral blood stem cell mobilisation using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br. J. Haematol., 85, 210-212.
6. DUNPHY FR, SPITZER G, ROSSITER FORNOFF JE, YAU JC, HUAN SA, DICKE KA, BUZDAR AU AND HORTOBAGYI GN. (1994). Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer, 73, 2157-2167.
7. ELIAS AD, MAZANET R, WHEELER C, ANDERSON K, AYASH L, SCHWARTZ G, TEPLER I, PAP S, PELAEZ J, HUNT M, SCHNIPPER L, GRIFFIN J, FREI E AND ANTMAN K. (1991). GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support or high-dose chemotherapy: two protocols. Breast Cancer Res. Treat., 20, S25-S29.
8. FREI E, III, ANTMAN K, TEICHER B, EDER P AND SCHNIPPER L. (1989). Bone marrow autotransplantation for solid tumours prospects. J. Clin. Oncol., 7, 515-526.
9. GABRA H, CAMERON DA, LEE LE, MACKAY J AND LEONARD RCF. (1996). Weekly doxorubicin and continuous infusional 5-FU for advanced breast cancer. Br. J. Cancer (submitted).
10. GREGORY WM, SMITH P, RICHARDS MA, TWELVES CJ, KNIGHT RK AND RUBENS RD. (1993). Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br. J. Cancer, 68, 988-995.
11. HESTER JP AND WALLERSTEIN RO. (1993). Peripheral blood stem cell transplantation for breast cancer patients with bone marrow metastases using GM-CSF priming. Transfus. Sci., 14, 65-69.
12. HRYNIUK WM AND BUSH H. (1984). The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2, 1281-1287.
13. JACKSON GH, LENNARD AL, TAYLOR PRA, CAREY B, ANGUS B, LUCRAFT H, EVANS RGB AND PROCTOR SJ. (1994). Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Br. J. Cancer, 70, 501-505.
14. JONES AL, SMITH IE, O'BRIEN MER, TALBOT D, WALSH G, RAMAGE F, ROBERTSHAW H AND ASHLEY S. (1994). Phase-II study of continuous-infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer - an active new regimen. J. Clin. Oncol., 12, 1259-1265.
15. KRITZ A, CROWN JP, MOTZER RJ, REICH LM, HELLER G, MOORE MP, HAMILTON N, YAO TJ, HEELEN RT, SCHNEIDER JG, MOORE MAS, MCCORMICK B, GILEWSKI TA, O'REILLY RJ, GULATI SC AND NORTON L. (1993). Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte macrophage colony-stimulating factor. Cancer, 71, 2515-2521.
16. LAZARUS HM, REED MD, SPITZER TR, RABAA MS AND BLUMER JL. (1987). High-dose iv thiotepa and cryopreserved autolgous bone marrow transplantation of refractory cancer. Cancer Treat. Rep., 71, 689-695.
17. LIVINGSTON RB. (1994). High-dose consolidation for stage IV breast cancer. In: American Society of Clinical Oncology Educational Book, Gastineau DA and Ramsay NK. (eds) pp. 74-79. Bostrom: Dallas.
18. MYERS SE, MICK R AND WILLIAMS SF. (1994). High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Bone Marrow Transplant, 13, 449-454.
19. PETERS W, SHPALL E, JONES R, OLSEN GA, BAST RC, GOCKERMAN JP AND MOORE JO. (1988). High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol., 6, 1368-1376.
20. SCHMITZ N, LINCH DC, DREGER P, BOOGAERTS MA, GOLDSTONE AH, FERRANT A, DEMUYNCK HMS, LINK H, ZANDER A AND MATCHAM J. (1994). A randomised phase-III study of filgrastim-mobilized peripheral-blood progenitor-cell transplantation (pbpct) in comparison with autologous bone-marrow transplantation (abmt) in patients with hodgkins-disease (hd) and non-hodgkins lymphoma (nhl). Blood, 84, 204A (abstract 802).
21. SOMLO G, DOROSHOW JH, FORMAN SJ, LEONG LA, MARGOLIN KA, MORGAN RJ, Jr, RASCHKO JW, AKMAN SA, AHN C, NAGASAWA S AND HARRISON J. (1994). High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer, 73, 1678-1685.
22. TANAKA J, TEICHER BA AND HERMAN TS. (1991). Etoposide with Ionidamine or pentoxifylline as modulators of aklylating agent activity in vivo. Int. J. Cancer, 48, 631-637.
23. TANNIR N, SPITZER G, DICKE K, SCHELL F, DISTEFANO A AND BLUMENSHEIN G. (1984). Phase I-II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat. Rep., 68, 805-806.
24. VAN DER WALL E, NOOIJEN WJ, BAARS JW, MOLTKAMP MJ, SCHORNAGEL JH, RICHEL DJ, RUTGERS EJT, SLAPER-CORTENBACH ICM, VAN DER SCHOOT CE AND RODENHUIS S. (1995). High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br. J. Cancer, 71, 857-862.
25. VINCENT MD, TREVOR J, POWLES R, COOMBES R AND MCELWAIN T. (1988). Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother. Pharmacol., 21, 255-260.